Novartis Licensed Preclinical Radioligand Asset
The agreement grants Novartis global rights to a preclinical therapy, with BoomRay potentially receiving $900 million.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe pharmaceutical company partnerships accelerate the availability of new medical treatments?
BoomRay Pharmaceuticals has entered into an exclusive global license agreement with Novartis for an undisclosed preclinical radioligand therapy asset. The deal allows BoomRay to earn up to $900 million in combined upfront, development, regulatory, and sales milestone payments.
Why it matters
This partnership aims to accelerate the advancement of emerging radioligand treatments by pairing external discovery with established global development resources. The collaboration underscores the current industry focus on integrating specialized preclinical research into broader pharmaceutical pipelines.
BoomRay is eligible for $900 million in total milestone-based compensation tied to a preclinical radioligand asset. The specific development timeline and the target receptor for the therapy are not currently available.
The players
BoomRay Pharmaceuticals
A Suzhou-based biotechnology firm focused on the discovery and development of oncology and radioligand therapeutics.
Novartis
A global pharmaceutical company with an extensive portfolio in oncology and a specialized focus on radioligand therapy development.
BFC Group
A financial advisory firm that acted as the lead advisor for BoomRay during the licensing process.
The details
The agreement leverages the discovery and development capabilities of Suzhou-based BoomRay to supply a novel asset for the Novartis radioligand therapeutic platform. Radioligand therapy functions by binding a radioisotope to a targeting molecule, which then delivers radiation specifically to diseased cells while minimizing exposure to surrounding healthy tissue. This arrangement effectively merges BoomRay research with Novartis global clinical trial infrastructure and manufacturing reach.
Timeline
September 22, 2026: BoomRay announced the global license agreement with Novartis.
The Tech Race
This agreement expands the Novartis radioligand therapy platform by integrating a new preclinical asset into its research roadmap. The acquisition represents a continued effort by Novartis to secure early-stage innovation to maintain its lead in the competitive radiopharmaceutical sector.
The development of this asset remains in the preclinical stage, meaning it is not currently available for clinical use or treatment. Patients and clinicians should monitor for future regulatory filings or trial announcements from Novartis regarding the program's progress.
The takeaway
This deal highlights the high market value currently placed on preclinical radioligand discovery assets. Observers should track Novartis for future clinical trial registrations that will signal the asset's transition from research to human testing.
Further reading
For more on the current state of radiopharmaceutical research, visit the Biotech section.
More information
Find additional details about the company's pipeline and operations at the Boomray Pharmaceuticals corporate website.
Live Poll
Do you believe pharmaceutical company partnerships accelerate the availability of new medical treatments?
